Associated equity: Basilea Pharmaceutica
Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.
Basilea Pharmaceutica — 12 videos in collection
Basilea Pharmaceutica (SIX:BSLN) is a commercial-stage biopharmaceutical R&D company focused on treating infectious diseases. Its core marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). The company continues to innovate to address unmet medical needs, leveraging management’s strong expertise in antifungals and antibiotics.
In this video, Basilea’s chief executive officer, David Veitch, and chief financial officer, Adesh Kaul, provide a brief introduction while addressing a few frequently asked questions.
Edison will be hosting the Basilea team in San Francisco for Healthcare Week on January 8-10, 2024. To request a 1×1 meeting with the Basilea team, please click here.
To learn more about Basilea, please access Edison’s content here.